• Earlier this month, Regeneron Pharmaceuticals and Sanofi announced that the European Commission approved Dupixent for moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years who do not respond adequately to standard antihistamines and are naive to anti-IgE therapy.
• This decision broadens Dupixent’s reach into a pediatric population with limited treatment options, reinforcing its role as a key immunology asset across multiple age groups and indications.
• We’ll now explore how this expanded pediatric approval for Dupixent in Europe fits into Regeneron’s broader investment narrative and growth ambitions.

AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Regeneron Pharmaceuticals Investment Narrative Recap

To own Regeneron, you need to believe it can offset pressure on EYLEA with its next wave of immunology and oncology products while keeping margins resilient despite higher R&D and pricing headwinds. The new EU pediatric approval for Dupixent in chronic spontaneous urticaria broadens an already important franchise, but does not fundamentally change the near term focus on EYLEA competition and pipeline execution risk.

Among recent updates, the expanded dosing label for EYLEA HD, allowing longer intervals in wAMD and DME, is especially relevant here. It speaks directly to Regeneron’s effort to defend and gradually transition its ophthalmology revenue base while Dupixent’s label growth, including this pediatric CSU approval, helps diversify away from a single product cluster that is under increasing competitive and pricing pressure.

Yet despite these wins, investors should be aware that longer term pricing pressure on Dupixent and EYLEA could still...

Regeneron Pharmaceuticals' narrative projects $18.7 billion revenue and $6.0 billion earnings by 2029.

Uncover how Regeneron Pharmaceuticals' forecasts yield a $873.78 fair value, a 16% upside to its current price.

Exploring Other Perspectives

By contrast, the most cautious analysts were assuming only about 5.9% annual revenue growth to roughly US$17.0 billion and modest margin compression, so this kind of news could challenge or reinforce that more pessimistic view depending on how you think Dupixent’s broader reach balances those longer term pricing and competition risks.

Explore 9 other fair value estimates on Regeneron Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Regeneron Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Regeneron Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Capitalize on the AI infrastructure supercycle with our selection of the 38 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Uncover the next big thing with 26 elite penny stocks that balance risk and reward.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.